JP6767096B2 - 免疫チェックポイント阻害剤の組み合わせ - Google Patents

免疫チェックポイント阻害剤の組み合わせ Download PDF

Info

Publication number
JP6767096B2
JP6767096B2 JP2015118495A JP2015118495A JP6767096B2 JP 6767096 B2 JP6767096 B2 JP 6767096B2 JP 2015118495 A JP2015118495 A JP 2015118495A JP 2015118495 A JP2015118495 A JP 2015118495A JP 6767096 B2 JP6767096 B2 JP 6767096B2
Authority
JP
Japan
Prior art keywords
ltx
cells
tumor
peptide
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015118495A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016128399A5 (enExample
JP2016128399A (ja
Inventor
マリエ エイク リヴ
マリエ エイク リヴ
カミリオ ケティル
カミリオ ケティル
スヴェインブジョルソン バルドル
スヴェインブジョルソン バルドル
ジトヴォゲル ローレンス
ジトヴォゲル ローレンス
ヤマザキ タカヒロ
ヤマザキ タカヒロ
レクダル オイステン
レクダル オイステン
シガード ムジョン スヴェンドセン ジョン
シガード ムジョン スヴェンドセン ジョン
Original Assignee
リティックス バイオファーマ エイエス
リティックス バイオファーマ エイエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1506127.8A external-priority patent/GB201506127D0/en
Application filed by リティックス バイオファーマ エイエス, リティックス バイオファーマ エイエス filed Critical リティックス バイオファーマ エイエス
Priority to LTEP15793746.7T priority Critical patent/LT3230318T/lt
Priority to ES15793746T priority patent/ES2819282T3/es
Priority to PCT/EP2015/075722 priority patent/WO2016091487A1/en
Priority to EP15793746.7A priority patent/EP3230318B1/en
Priority to AU2015359881A priority patent/AU2015359881B2/en
Priority to PL15793746T priority patent/PL3230318T3/pl
Priority to DK15793746.7T priority patent/DK3230318T3/da
Priority to HUE15793746A priority patent/HUE051268T2/hu
Priority to PT157937467T priority patent/PT3230318T/pt
Priority to US15/534,800 priority patent/US11083774B2/en
Publication of JP2016128399A publication Critical patent/JP2016128399A/ja
Publication of JP2016128399A5 publication Critical patent/JP2016128399A5/ja
Priority to AU2019203199A priority patent/AU2019203199B2/en
Publication of JP6767096B2 publication Critical patent/JP6767096B2/ja
Application granted granted Critical
Priority to AU2021204356A priority patent/AU2021204356B2/en
Priority to US17/366,463 priority patent/US20230201305A9/en
Priority to US18/598,719 priority patent/US12239686B2/en
Priority to US19/022,157 priority patent/US20250332217A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015118495A 2014-12-11 2015-06-11 免疫チェックポイント阻害剤の組み合わせ Active JP6767096B2 (ja)

Priority Applications (15)

Application Number Priority Date Filing Date Title
HUE15793746A HUE051268T2 (hu) 2014-12-11 2015-11-04 Immunellenõrzõpont-gátló kombinációk
US15/534,800 US11083774B2 (en) 2014-12-11 2015-11-04 Immune checkpoint inhibitor combinations
ES15793746T ES2819282T3 (es) 2014-12-11 2015-11-04 Combinaciones de inhibidores de puntos de control inmunitarios
PCT/EP2015/075722 WO2016091487A1 (en) 2014-12-11 2015-11-04 Immune checkpoint inhibitor combinations
EP15793746.7A EP3230318B1 (en) 2014-12-11 2015-11-04 Immune checkpoint inhibitor combinations
AU2015359881A AU2015359881B2 (en) 2014-12-11 2015-11-04 Immune checkpoint inhibitor combinations
PL15793746T PL3230318T3 (pl) 2014-12-11 2015-11-04 Kombinacje inhibitora immunologicznego punktu kontrolnego
DK15793746.7T DK3230318T3 (da) 2014-12-11 2015-11-04 Immune checkpoint-inhibitor-kombinationer
LTEP15793746.7T LT3230318T (lt) 2014-12-11 2015-11-04 Imuninės kontrolės taško inhibitorių kombinacijos
PT157937467T PT3230318T (pt) 2014-12-11 2015-11-04 Combinações de inibidores de pontos de controlo imunitários
AU2019203199A AU2019203199B2 (en) 2014-12-11 2019-05-07 Immune checkpoint inhibitor combinations
AU2021204356A AU2021204356B2 (en) 2014-12-11 2021-06-25 Immune checkpoint inhibitor combinations
US17/366,463 US20230201305A9 (en) 2014-12-11 2021-07-02 Immune checkpoint inhibitor combinations
US18/598,719 US12239686B2 (en) 2014-12-11 2024-03-07 Immune checkpoint inhibitor combinations
US19/022,157 US20250332217A1 (en) 2014-12-11 2025-01-15 Immune checkpoint inhibitor combinations

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB201422084 2014-12-11
GB1422084.2 2014-12-11
GB1506127.8 2015-04-10
GBGB1506127.8A GB201506127D0 (en) 2015-04-10 2015-04-10 Immune checkpoint inhibitor combinations

Publications (3)

Publication Number Publication Date
JP2016128399A JP2016128399A (ja) 2016-07-14
JP2016128399A5 JP2016128399A5 (enExample) 2018-05-10
JP6767096B2 true JP6767096B2 (ja) 2020-10-14

Family

ID=56384106

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015118495A Active JP6767096B2 (ja) 2014-12-11 2015-06-11 免疫チェックポイント阻害剤の組み合わせ

Country Status (11)

Country Link
US (4) US11083774B2 (enExample)
EP (1) EP3230318B1 (enExample)
JP (1) JP6767096B2 (enExample)
AU (3) AU2015359881B2 (enExample)
DK (1) DK3230318T3 (enExample)
ES (1) ES2819282T3 (enExample)
HU (1) HUE051268T2 (enExample)
LT (1) LT3230318T (enExample)
PL (1) PL3230318T3 (enExample)
PT (1) PT3230318T (enExample)
WO (1) WO2016091487A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6767096B2 (ja) * 2014-12-11 2020-10-14 リティックス バイオファーマ エイエス 免疫チェックポイント阻害剤の組み合わせ
EP3560513A4 (en) 2016-12-26 2020-10-14 National University Corporation Kobe University ANTICANCER THERAPY USING A COMBINATION OF AN ORAL TUMOR VACCINE AND AN IMMUNOSUPPRESSION INHIBITOR
WO2018188761A1 (en) * 2017-04-13 2018-10-18 Lytix Biopharma As Method of reducing population size of tregs and/or mdscs
CN119868398A (zh) 2018-06-14 2025-04-25 株式会社明治 用于促进免疫检查点抑制疗法的组合物
BR112021022659A2 (pt) 2019-05-15 2022-03-29 Chemocentryx Inc Compostos triarílicos para o tratamento de doenças pd-l1
KR102841588B1 (ko) 2019-06-20 2025-08-01 케모센트릭스, 인크. Pd-l1 질환의 치료를 위한 화합물
CN110317245B (zh) * 2019-08-02 2021-04-09 郑州大学 Lag-3蛋白亲和环肽及其应用
ES3068390T3 (en) 2019-10-16 2026-05-29 Chemocentryx Inc Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
AU2020368392B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
US20230037966A1 (en) * 2020-01-07 2023-02-09 The Trustees Of The University Of Pennsylvania Source specific exosomes for determining avoidance of cancer treatment and avoidance of checkpoint inhibitor therapies
AU2023413685A1 (en) 2022-12-20 2025-06-19 Lytix Biopharma As Compositions comprising an oncolytic peptide and chitosan
EP4637799A1 (en) 2022-12-20 2025-10-29 Lytix Biopharma AS Medical products containing an aqueous formulation of a peptide
CN117402828A (zh) * 2023-04-13 2024-01-16 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种人肺癌脑转移瘤细胞系及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
CA2328507A1 (en) 1998-05-04 1999-11-11 Thomas Jefferson University Use of a composition comprising tumor cells or tumor cell extracts for inducing an anti-tumor response in a mammalian patient
GB0605685D0 (en) * 2006-03-21 2006-05-03 Lytix Biopharma As Inhibition of tumour growth
DE60334303D1 (de) * 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
WO2011041613A2 (en) * 2009-09-30 2011-04-07 Memorial Sloan-Kettering Cancer Center Combination immunotherapy for the treatment of cancer
US9410206B2 (en) * 2011-11-30 2016-08-09 John Wayne Cancer Institute Long noncoding RNA (lncRNA) as a biomarker and therapeutic marker in cancer
US10202454B2 (en) * 2013-10-25 2019-02-12 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
EP3107576A4 (en) * 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
MX2017007535A (es) * 2014-12-09 2017-08-10 Merck Sharp & Dohme Sistema y metodos para derivar biomarcadores de firmas geneticas de la respuesta a antagonistas de muerte programada 1 (pd-1).
JP6767096B2 (ja) * 2014-12-11 2020-10-14 リティックス バイオファーマ エイエス 免疫チェックポイント阻害剤の組み合わせ
JP6813258B2 (ja) * 2014-12-11 2021-01-13 リティックス バイオファーマ エイエス 化学療法の組み合わせ

Also Published As

Publication number Publication date
AU2015359881A1 (en) 2017-07-20
ES2819282T3 (es) 2021-04-15
US20240293506A1 (en) 2024-09-05
US12239686B2 (en) 2025-03-04
EP3230318B1 (en) 2020-06-24
US20230201305A9 (en) 2023-06-29
PT3230318T (pt) 2020-09-21
US11083774B2 (en) 2021-08-10
AU2015359881B2 (en) 2019-02-07
AU2019203199B2 (en) 2021-04-01
AU2019203199A1 (en) 2019-05-30
US20250332217A1 (en) 2025-10-30
HUE051268T2 (hu) 2021-03-01
DK3230318T3 (da) 2020-08-31
AU2021204356B2 (en) 2024-10-03
US20210401933A1 (en) 2021-12-30
EP3230318A1 (en) 2017-10-18
LT3230318T (lt) 2020-10-12
US20180264079A1 (en) 2018-09-20
WO2016091487A1 (en) 2016-06-16
AU2021204356A1 (en) 2021-07-22
PL3230318T3 (pl) 2021-03-08
JP2016128399A (ja) 2016-07-14

Similar Documents

Publication Publication Date Title
US12239686B2 (en) Immune checkpoint inhibitor combinations
JP5798919B2 (ja) Ｐｄ−１アンタゴニストの組成物および使用方法
KR101445910B1 (ko) 항종양 활성을 가지는 나노펩티드
US20250002854A1 (en) Methods of generating populations of tumour-infiltrating t cells
JP2021513853A (ja) 癌免疫療法のためのチェックポイント遮断としての操作されたナノベシクル
CA3001174A1 (en) Use of peptides to stimulate the immune system
WO2016091490A1 (en) Chemotherapeutic combinations of cationic antimicrobial peptides and chemotherapeutics
JP6813258B2 (ja) 化学療法の組み合わせ
US20250066420A1 (en) Pd-l1 inhibitory peptide for cancer immunotherapy
KR20230039787A (ko) 생체분자의 안정적 발현 및 전달을 위한 플라스미드 플랫폼

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20150708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190719

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200207

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200221

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200313

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200807

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200825

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200917

R150 Certificate of patent or registration of utility model

Ref document number: 6767096

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250